Max Healthcare shares rose over 3% to Rs 1,047 following an upgrade from UBS, which changed its rating from 'Neutral' to 'Buy' and set a target price of Rs 1,200, indicating an 18.3% upside. The brokerage highlighted the company's strong growth potential, driven by plans to double bed capacity and an efficient asset-light model, despite a 17.4% decline in net profit for Q3. Revenue, however, surged by 39.9% year-on-year, reaching Rs 1,868.3 crore.